GlassScriptPhysician profile
Derek M Mcmurry
NPI 1649379744
$4,167.77
in general payments reported to CMS, 2019-2025
26 companies · $581 in 2025
The $581 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $94.80 · 2021: $1,049 · 2022: $767 · 2023: $918 · 2024: $758 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,256.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $1,099.98 | 2021-2025 | Xtampza, Belbuca |
| Abbvie INC. | $1,024.96 | 2021-2025 | |
| Pfizer INC. | $255.55 | 2021-2025 | |
| Amgen INC. | $231.43 | 2020-2021 | |
| Abbott Laboratories | $213.89 | 2021-2025 | Proclaim, Eterna |
| Vertos Medical, INC. | $188.86 | 2021-2024 | Mild Device Kit |
| Biohaven Pharmaceuticals, INC. | $125.60 | 2021 | |
| Medtronic, INC. | $122.35 | 2021-2025 | Intellis Adaptivestim, Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.98 | 2021-2024 | Relistor |
| Averitas Pharma INC. | $97.61 | 2024-2025 | Qutenza |
| Boston Scientific Corporation | $97.45 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $84.53 | 2025 | |
| Grt US Holding, INC. | $72.19 | 2022 | |
| Ibsa Pharma INC. | $70.45 | 2022-2024 | Tirosint, Licart, Tirosint |
| Tersera Therapeutics LLC | $70.30 | 2022-2023 | Prialt |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $53.52 | 2022 | |
| Amneal Pharmaceuticals LLC | $48.24 | 2023 | Lyvispah |
| Curonix LLC | $37.43 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Scilex Pharmaceuticals INC. | $31.51 | 2023-2025 | Ztlido |
| Lundbeck LLC | $27.66 | 2024 | Vyepti |
| Merz Pharmaceuticals, LLC | $22.31 | 2024 | Xeomin |
| Stryker Corporation | $19.18 | 2024 | Mild Device Kit |
| Tonix Medicines, INC. | $15.96 | 2025 | Tonmya |
| Lilly USA, LLC | $15.11 | 2023 | Reyvow, Emgality |
| Spr Therapeutics, INC | $14.26 | 2020 | |
| Depuy Synthes Sales INC. | $13.46 | 2025 | Orthovisc, Monovisc |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Mcmurry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.